XNAS 29 Aug, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Uwe Klein | SVP, Biological Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.76 per share. | 18 Aug 2025 | 4,935 | 15,387 | - | 2.8 | 13,621 | Common Stock |
| Uwe Klein | SVP, Biological Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.81 per share. | 18 Aug 2025 | 7,621 | 23,008 | - | 6.8 | 51,899 | Common Stock |
| Uwe Klein | SVP, Biological Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2025 | 10,452 | 10,453 | - | - | Stock Option (Right to Buy) | |
| Uwe Klein | SVP, Biological Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2025 | 4,935 | 9,001 | - | - | Stock Option (Right to Buy) | |
| Uwe Klein | SVP, Biological Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2025 | 7,621 | 33,027 | - | - | Stock Option (Right to Buy) | |
| Uwe Klein | SVP, Biological Sciences | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.76 per share. | 18 Aug 2025 | 10,452 | 10,452 | - | 2.8 | 28,848 | Common Stock |
| Uwe Klein | SVP, Biological Sciences | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2025 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Gil M. Labrucherie | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2025 | 37,500 | 37,500 | - | - | Stock Option (Right to Buy) | |
| Jeffrey T. Finer | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2025 | 210,000 | 210,000 | - | - | Stock Option (Right to Buy) | |
| Jae B. Kim | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2025 | 55,000 | 55,000 | - | - | Stock Option (Right to Buy) | |
| Samira Shaikhly | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2025 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Daniel Long | SVP, Drug Discovery | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2025 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Shalini Sharp | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2025 | 16,623 | 16,623 | - | - | Stock Option (Right to Buy) | |
| Abraham Bassan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2025 | 16,623 | 16,623 | - | - | Stock Option (Right to Buy) | |
| Jake Simson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2025 | 16,623 | 16,623 | - | - | Stock Option (Right to Buy) | |
| Bernard Coulie | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2025 | 16,623 | 16,623 | - | - | Stock Option (Right to Buy) | |
| Alan Ezekowitz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2025 | 16,623 | 16,623 | - | - | Stock Option (Right to Buy) | |
| Jeffrey T. Finer | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.76 per share. | 02 Apr 2025 | 50,000 | 821,907 | - | 2.8 | 138,000 | Common Stock |
| Jeffrey T. Finer | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.76 per share. | 02 Apr 2025 | 5,000 | 826,907 | - | 2.8 | 13,800 | Common Stock |
| Jeffrey T. Finer | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Apr 2025 | 50,000 | 402,212 | - | - | Stock Option (Right to Buy) | |
| Jeffrey T. Finer | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Apr 2025 | 5,000 | 397,212 | - | - | Stock Option (Right to Buy) | |
| Alan Ezekowitz | Director | Purchase of securities on an exchange or from another person at price $ 6.93 per share. | 07 Mar 2025 | 13,319 | 117,420 | - | 6.9 | 92,270 | Common Stock |
| Alan Ezekowitz | Director | Purchase of securities on an exchange or from another person at price $ 5.82 per share. | 04 Mar 2025 | 37,835 | 62,746 | - | 5.8 | 220,260 | Common Stock |
| Alan Ezekowitz | Director | Purchase of securities on an exchange or from another person at price $ 6.35 per share. | 04 Mar 2025 | 7,491 | 24,911 | - | 6.3 | 47,544 | Common Stock |
| Alan Ezekowitz | Director | Purchase of securities on an exchange or from another person at price $ 6.00 per share. | 04 Mar 2025 | 41,355 | 104,101 | - | 6 | 248,130 | Common Stock |
| Jeffrey T. Finer | Director, CEO and President | Purchase of securities on an exchange or from another person at price $ 5.80 per share. | 25 Feb 2025 | 3,000 | 771,907 | - | 5.8 | 17,400 | Common Stock |
| Jeffrey T. Finer | Director, CEO and President | Purchase of securities on an exchange or from another person at price $ 5.70 per share. | 25 Feb 2025 | 4,000 | 768,907 | - | 5.7 | 22,796 | Common Stock |
| Jeffrey T. Finer | Director, CEO and President | Purchase of securities on an exchange or from another person at price $ 5.68 per share. | 25 Feb 2025 | 10,000 | 764,907 | - | 5.7 | 56,765 | Common Stock |
| Gil M. Labrucherie | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 5.85 per share. | 25 Feb 2025 | 3,718 | 40,000 | - | 5.8 | 21,750 | Common Stock |
| Gil M. Labrucherie | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 5.59 per share. | 25 Feb 2025 | 6,282 | 36,282 | - | 5.6 | 35,116 | Common Stock |
| Gil M. Labrucherie | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 5.85 per share. | 19 Feb 2025 | 5,000 | 30,000 | - | 5.9 | 29,250 | Common Stock |
| Gil M. Labrucherie | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 5.88 per share. | 19 Feb 2025 | 14,500 | 25,000 | - | 5.9 | 85,234 | Common Stock |
| Gil M. Labrucherie | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 5.51 per share. | 19 Feb 2025 | 10,500 | 10,500 | - | 5.5 | 57,813 | Common Stock |
| Gil M. Labrucherie | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2025 | 222,000 | 222,000 | - | - | Stock Option (Right to Buy) |